# Solstice Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/solstice-biologics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.solsticebio.com
- Total disclosed funding: $18M
- Latest round: Series A (Jan 4, 2013)
- Investors on record: 2

## About

Solstice Biologics is a biotechnology firm specializing in premium domain names for the life sciences sector, facilitating enhanced online credibility and visibility for businesses in this competitive field.Founded in 2012, Solstice Biologics operates out of San Diego, US, and focuses on providing premium domain names. The company raised USD 4.00 mn in Series A funding on December 30, 2015, which constitutes the total amount raised to date. It has engaged in two deals since its inception.Solstice Bio offers the premium domain name solsticebio.com, targeting businesses in the biotechnology and life sciences sectors. This domain serves as an essential digital asset for establishing strong online identities, appealing to a global audience, particularly in North America, Europe, and growing Asian markets.Revenue for Solstice Bio originates from the sale of premium domain names, notably solsticebio.com. The domain is available for a one-time payment of USD 2,995, with transactions secured through Efty Pay, ensuring safe payment handling until the domain transfer is completed.Looking ahead, Solstice Biologics aims to expand its offerings by introducing new premium domains tailored to emerging biotech niches. The recent Series A funding will support these initiatives, alongside plans to penetrate additional markets in Asia and Europe by 2024.

## Funding rounds

- Series A, Jan 4, 2013, $18M — Aeris Capital, VenBio

## Investors

- Aeris Capital — Series A
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A